TNFRSF8 and hematopoietic and lymphoid cell neoplasm: Another ADC approved for hematological cancers, brentuximab vedotin (AdcetrisTM) targets CD30, a member of tumor necrosis factor receptor superfamily (TNFRSF) expressed on activated B cells, T cells, and NK cells, as well as a number of T- and B-cell malignancies, including Hodgkin lymphoma and anaplastic large cell lymphoma.